Phospholipid biomarkers in the diagnosis of patients with Alzheimer's disease
DOI:
https://doi.org/10.31117/neuroscirn.v9i1.462Keywords:
Biomarkers, Alzheimer’s disease, Diagnosis, PhospholipidsAbstract
Alzheimer's disease is a neurodegenerative disease characterized by an accumulation of amyloid beta peptide and hyperphosphorylation of Tau protein, as well as alterations in lipids that are important components of cell membranes. However, the mechanism of phospholipids in AD is not yet fully understood. This mini-review aims to explore the role of phospholipid biomarkers in the diagnosis, prognosis, and progression of the disease. A search was performed in several databases, including PubMed, PubMed Central, and ScienceDirect, with keywords such as "phospholipid biomarkers," "Alzheimer," and "non-sporadic diagnosis." A total of 30 articles were found, in which we discovered that phospholipid species such as ceramides, sphingomyelins, phosphatidylcholines, lysophosphatidylcholines, ethanolamine plasmalogens, phosphatidylethanolamines, and 2-aminoethyl dihydrogen phosphate were altered, showing that plasma lipids can be used as biomarkers for the diagnosis of AD, as well as to predict the prognosis and classify the severity of the disease. Nevertheless, although the findings are promising, further clinical validation through larger, more extensive studies is still required to consolidate their diagnostic and prognostic applications.
Downloads
References
Agarwal, M., & Khan, S. (2020). Plasma lipids as biomarkers for Alzheimer’s disease: A systematic review. Cureus, 12(12), e12008. https://doi.org/10.7759/cureus.12008
Banack, S. A., Stark, A. C., & Cox, P. A. (2022). A possible blood plasma biomarker for early-stage Alzheimer’s disease. PLoS One, 17(4), e0267407. https://doi.org/10.1371/journal.pone.0267407
Bennett, S. A. L., Valenzuela, N., Xu, H., Franko, B., Fai, S., & Figeys, D. (2013). Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer’s Disease. Frontiers in Physiology, 4, 168. https://doi.org/10.3389/fphys.2013.00168
Ceccom, J., Delisle, M.-B., & Cuvillier, O. (2014). Sphingosine 1-phosphate as a biomarker for Alzheimer’s disease? Medecine Sciences, 30(5), 493–495. https://doi.org/10.1051/medsci/20143005006
Chen, Y., Lin, C., Guo, Z., Zhao, S., Zhu, Y., Huang, F., Shui, G., Lam, S. M., Pu, J., Yan, Y., Liu, Z., & Zhang, B. (2020). Altered expression profile of phosphatidylinositols in erythrocytes of Alzheimer’s Disease and amnestic mild cognitive impairment patients. Journal of Alzheimer’s Disease, 73(2), 811-818. https://doi.org/10.3233/JAD-190926
Cui, Y., Liu, X., Wang, M., Liu, L., Sun, X., Ma, L., Xie, W., Wang, C., Tang, S., Wang, D., & Wu, Q. (2014). Lysophosphatidylcholine and amide as metabolites for detecting alzheimer disease using ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabonomics. Journal of Neuropathology and Experimental Neurology, 73(10), 954–963. https://doi.org/10.1097/NEN.0000000000000116
Czubowicz, K., Jęśko, H., Wencel, P., Lukiw, W. J., & Strosznajder, R. P. (2019). The role of ceramide and sphingosine-1-phosphate in Alzheimer’s Disease and other neurodegenerative disorders. Molecular Neurobiology, 56(8), 5436-5455. https://doi.org/10.1007/s12035-018-1448-3
Dakterzada, F., Benítez, I. D., Targa, A., Carnes, A., Pujol, M., Jové, M., Mínguez, O., Vaca, R., Sánchez-de-la-Torre, M., Barbé, F., Pamplona, R., & Piñol-Ripoll, G. (2022). Blood-based lipidomic signature of severe obstructive sleep apnoea in Alzheimer’s disease. Alzheimer’s Research & Therapy, 14(1), 163. https://doi.org/10.1186/s13195-022-01102-8
Dorninger, F., Moser, A. B., Kou, J., Wiesinger, C., Forss-Petter, S., Gleiss, A., Hinterberger, M., Jungwirth, S., Fischer, P., & Berger, J. (2018). Alterations in the plasma levels of specific choline phospholipids in Alzheimer’s disease mimic accelerated aging. Journal of Alzheimer’s Disease, 62(2), 841–854. https://doi.org/10.3233/JAD-171036
Gaitán, J. M., Moon, H. Y., Stremlau, M., Dubal, D. B., Cook, D. B., Okonkwo, O. C., & van Praag, H. (2021). Effects of aerobic exercise training on systemic biomarkers and cognition in late middle-aged adults at risk for Alzheimer’s disease. Frontiers in Endocrinology, 12, 660181. https://doi.org/10.3389/fendo.2021.660181
González-Domínguez, R., García-Barrera, T., & Gómez-Ariza, J. L. (2014). Using direct infusion mass spectrometry for serum metabolomics in Alzheimer’s disease. Analytical and Bioanalytical Chemistry, 406(28), 7137–7148. https://doi.org/10.1007/s00216-014-8102-3
Han, X. (2005). Lipid alterations in the earliest clinically recognizable stage of Alzheimer’s disease: Implication of the role of lipids in the pathogenesis of Alzheimer’s disease. Current Alzheimer Research, 2(1), 65-77. https://doi.org/10.2174/1567205052772786
Han, X., Fagan, A. M., Cheng, H., Morris, J. C., Xiong, C., & Holtzman, D. M. (2003). Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Annals of Neurology, 54(1), 115–119. https://doi.org/10.1002/ana.10618
Khan, M. J., Chung, N. A., Hansen, S., Dumitrescu, L., Hohman, T. J., Kamboh, M. I., Lopez, O. L., & Robinson, R. A. S. (2022). Targeted lipidomics to measure phospholipids and sphingomyelins in plasma: A pilot study to understand the impact of race/ethnicity in Alzheimer’s disease. Analytical Chemistry, 94(10), 4165–4174. https://doi.org/10.1021/acs.analchem.1c03821
Kim, M., Nevado-Holgado, A., Whiley, L., Snowden, S. G., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Thambisetty, M., Dobson, R. J. B., Powell, J. F., Lupton, M. K., Simmons, A., Velayudhan, L., Lovestone, S., Proitsi, P., & Legido-Quigley, C. (2017). Association between plasma ceramides and phosphatidylcholines and hippocampal brain volume in late-onset Alzheimer’s disease. Journal of Alzheimer’s Disease, 60(3), 809–817. https://doi.org/10.3233/JAD-160645
Kling, M. A., Goodenowe, D. B., Senanayake, V., Mahmoudian, D. S., Arnold, M., Massaro, T. J., Baillie, R., Han, X., Leung, Y. Y., Saykin, A. J., Nho, K., Kueider-Paisley, A., Tenenbaum, J. D., Wang, L. S., Shaw, L. M., Trojanowski, J. Q., & Kaddurah-Daouk, R. F. (2020). Circulating ethanolamine plasmalogen indices in Alzheimer’s disease: Relation to diagnosis, cognition, and CSF tau. Alzheimer’s & Dementia, 16(9), 1234–1247. https://doi.org/10.1002/alz.12110
Koal, T., Klavins, K., Seppi, D., Kemmler, G., & Humpel, C. (2015). Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-β42, tau, and phospho-tau-181 levels. Journal of Alzheimer’s Disease, 44(4), 1193–1201. https://doi.org/10.3233/JAD-142319
Kosicek, M., & Hecimovic, S. (2013). Phospholipids and Alzheimer’s disease: Alterations, mechanisms and potential biomarkers. International Journal of Molecular Sciences, 14(1), 1310–1322. https://doi.org/10.3390/ijms14011310
Kosicek, M., Kirsch, S., Bene, R., Trkanjec, Z., Titlic, M., Bindila, L., Peter-Katalinic, J., & Hecimovic, S. (2010). Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer’s disease patients—A pilot study. Analytical and Bioanalytical Chemistry, 398(7-8), 2929–2937. https://doi.org/10.1007/s00216-010-4273-8
Lord, J., Jermy, B., Green, R., Wong, A., Xu, J., Legido-Quigley, C., Dobson, R., Richards, M., & Proitsi, P. (2021). Mendelian randomization identifies blood metabolites previously linked to midlife cognition as causal candidates in Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 118(16), e2009808118. https://doi.org/10.1073/pnas.2009808118
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., Nazar, M. D., Rich, S. A., Berlau, D. J., Peltz, C. B., Tan, M. T., Kawas, C. H., & Federoff, H. J. (2014). Plasma phospholipids identify antecedent memory impairment in older adults. Nature Medicine, 20(4), 415–418. https://doi.org/10.1038/nm.3466
McIntyre, J. A., Wagenknecht, D. R., & Ramsey, C. J. (2009). Redox-reactive antiphospholipid antibody differences between serum from Alzheimer’s patients and age-matched controls. Autoimmunity, 42(8), 646–652. https://doi.org/10.3109/08916930903074833
Mielke, M. M., Bandaru, V. V. R., Haughey, N. J., Rabins, P. V., Lyketsos, C. G., & Carlson, M. C. (2010). Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiology of Aging, 31(1), 17–24. https://doi.org/10.1016/j.neurobiolaging.2008.03.011
Mielke, M. M., Haughey, N. J., Bandaru, V. V. R., Weinberg, D. D., Darby, E., Zaidi, N., Pavlik, V., Doody, R. S., & Lyketsos, C. G. (2011). Plasma sphingomyelins are associated with cognitive progression in Alzheimer’s disease. Journal of Alzheimer’s Disease, 27(2), 259–269. https://doi.org/10.3233/JAD-2011-110405
Orešič, M., Hyötyläinen, T., Herukka, S.-K., Sysi-Aho, M., Mattila, I., Seppänan-Laakso, T., Julkunen, V., Gopalacharyulu, P. V., Hallikainen, M., Koikkalainen, J., Kivipelto, M., Helisalmi, S., Lötjönen, J., & Soininen, H. (2011). Metabolome in progression to Alzheimer’s disease. Translational Psychiatry, 1(12), e57. https://doi.org/10.1038/tp.2011.55
Pettegrew, J. W., Panchalingam, K., Hamilton, R. L., & McClure, R. J. (2001). Brain membrane phospholipid alterations in Alzheimer’s disease. Neurochemical Research, 26(7), 771–782. https://doi.org/10.1023/a:1011603916962
Su, H., Rustam, Y. H., Masters, C. L., Makalic, E., McLean, C. A., Hill, A. F., Barnham, K. J., Reid, G. E., & Vella, L. J. (2021). Characterization of brain-derived extracellular vesicle lipids in Alzheimer’s disease. Journal of Extracellular Vesicles, 10(7), e12089. https://doi.org/10.1002/jev2.12089
Wong, M. W., Braidy, N., Poljak, A., & Sachdev, P. S. (2017). The application of lipidomics to biomarker research and pathomechanisms in Alzheimer’s disease. Current Opinion in Psychiatry, 30(2), 136–144. https://doi.org/10.1097/YCO.0000000000000303
Wood, P. L., Barnette, B. L., Kaye, J. A., Quinn, J. F., & Woltjer, R. L. (2015). Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer’s disease subjects. Acta Neuropsychiatrica, 27(5), 270–278. https://doi.org/10.1017/neu.2015.18
Wurtman, R. (2015). Biomarkers in the diagnosis and management of Alzheimer’s disease. Metabolism: Clinical and Experimental, 64(3 Suppl 1), S47-50. https://doi.org/10.1016/j.metabol.2014.10.034
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Rossi Geovo Robledo, Anibal Arteaga Noriega; Juan Habib Bendeck Soto; Johanna Andrea Gutierrez Vargas
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The observations and associated materials published or posted by NeurosciRN are licensed by the authors for use and distribution in accord with the Creative Commons Attribution license CC BY-NC 4.0 international, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
